Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1R polymorphisms and response to GLP-1 receptor agonists in type 2 diabetes
ChiCTR1800016610Phase 4Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Jun 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liraglutide and exenatide in type 2 diabetes mellitus (T2DM), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoints: GLP-1R genotype, Blood glucose and 1 more. Started Jun 2018; status: recruiting.
02
Drugs
liraglutideexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1800016610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016610.